{"id":"methotrexate-tapering-dose","safety":{"commonSideEffects":[{"rate":"10-30%","effect":"Myelosuppression (anemia, leukopenia, thrombocytopenia)"},{"rate":"10-25%","effect":"Mucositis / stomatitis"},{"rate":"10-20%","effect":"Nausea and vomiting"},{"rate":"5-15%","effect":"Hepatotoxicity"},{"rate":"5-10%","effect":"Nephrotoxicity"},{"rate":"5-10%","effect":"Neurotoxicity (CNS effects)"},{"rate":"5-10%","effect":"Alopecia"},{"rate":"5-15%","effect":"Infection"}]},"_chembl":{"chemblId":"CHEMBL2074969","moleculeType":"Small molecule","molecularWeight":"841.79"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By inhibiting dihydrofolate reductase, methotrexate prevents the conversion of dihydrofolate to tetrahydrofolate, disrupting one-carbon transfer reactions essential for nucleotide synthesis. This leads to suppression of rapidly dividing cells, including cancer cells and activated immune cells. At lower doses used in autoimmune conditions, it also exerts immunosuppressive effects through adenosine release and reduced T-cell proliferation.","oneSentence":"Methotrexate inhibits dihydrofolate reductase, blocking the synthesis of purines and pyrimidines required for DNA replication and cell division.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:54:41.769Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute lymphoblastic leukemia (ALL)"},{"name":"Osteosarcoma"},{"name":"Breast cancer"},{"name":"Lung cancer"},{"name":"Rheumatoid arthritis"},{"name":"Psoriasis"},{"name":"Crohn's disease"}]},"trialDetails":[{"nctId":"NCT02845882","phase":"PHASE3","title":"LBL-2016 for Children or Adolescents in China","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2016-01","conditions":"Lymphoblastic Lymphoma","enrollment":150},{"nctId":"NCT02114229","phase":"PHASE2","title":"Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2014-05-14","conditions":"Malignant Rhabdoid Tumor, Atypical Teratoid Rhabdoid Tumor","enrollment":125},{"nctId":"NCT05581030","phase":"PHASE1","title":"CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2023-05-01","conditions":"Acute Lymphoblastic Leukemia","enrollment":7},{"nctId":"NCT06037811","phase":"PHASE2","title":"Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis","status":"RECRUITING","sponsor":"Tom Appleton","startDate":"2024-04-15","conditions":"Inflammatory Arthritis, Immune-related Adverse Event","enrollment":30},{"nctId":"NCT07428551","phase":"PHASE4","title":"Comparative Study of Leflunomide Plus Methotrexate Versus Methotrexate Monotherapy in Refractory Polyarticular Juvenile Idiopathic Arthritis Patients","status":"COMPLETED","sponsor":"Bangladesh Medical University","startDate":"2024-03-01","conditions":"Juvenile Idiopathic Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Refractory Polyarticular Juvenile Idiopathic Arthritis","enrollment":50},{"nctId":"NCT03842696","phase":"PHASE1, PHASE2","title":"Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2020-02-04","conditions":"Hematologic Diseases, Acute Leukemia in Remission, Chronic Myelogenous Leukemia - Chronic Phase","enrollment":43},{"nctId":"NCT06001125","phase":"PHASE2","title":"Methotrexate for Immune Related Arthritis or Arthralgias (IMPACT 2.1)","status":"TERMINATED","sponsor":"AHS Cancer Control Alberta","startDate":"2024-08-12","conditions":"Arthritis, Arthralgia","enrollment":27},{"nctId":"NCT06528431","phase":"PHASE4","title":"Design and Evaluation of an Individualized Biodrug Tapering Strategy Based on Biodrug Dosage: the MONITORA Study","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2024-12-19","conditions":"Arthritis, Rheumatoid","enrollment":180},{"nctId":"NCT02356159","phase":"PHASE1, PHASE2","title":"Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2015-09-24","conditions":"Myelodysplastic Syndromes, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma","enrollment":34},{"nctId":"NCT04435288","phase":"PHASE3","title":"Spondyloarthritis: Inducing Drug-free Remission by Early TNF-alpha Blockade","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Ghent","startDate":"2020-08-24","conditions":"Peripheral Spondyloarthritis","enrollment":90},{"nctId":"NCT06172361","phase":"PHASE3","title":"Induction and Tapering Therapy With Tofacitinib and Glucocorticoid in Patients With Polymyalgia Rheumatica","status":"RECRUITING","sponsor":"Zhejiang University","startDate":"2024-01-20","conditions":"Polymyalgia Rheumatica","enrollment":98},{"nctId":"NCT06262438","phase":"PHASE2","title":"CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients","status":"RECRUITING","sponsor":"Princess Maxima Center for Pediatric Oncology","startDate":"2024-02-06","conditions":"Acute Myeloid Leukemia in Children","enrollment":60},{"nctId":"NCT03456817","phase":"PHASE2","title":"HIgh Dose Thymoglobulin Instead of Cyclosporine With a Low Dose of Thymoglobulin for GVHD Prophylaxis","status":"TERMINATED","sponsor":"AHS Cancer Control Alberta","startDate":"2020-07-01","conditions":"Graft-versus-host-disease, Relapse","enrollment":68},{"nctId":"NCT02494882","phase":"PHASE1","title":"Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2015-06-29","conditions":"Acute Lymphoblastic Leukemia","enrollment":12},{"nctId":"NCT03649061","phase":"PHASE4","title":"COBRA-Slim With or Without Fast Access to TNF Blockade for Remission Induction in Early RA","status":"COMPLETED","sponsor":"P. Verschueren","startDate":"2018-06-08","conditions":"Arthritis, Rheumatoid","enrollment":276},{"nctId":"NCT04329325","phase":"PHASE2","title":"Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-03-30","conditions":"Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Positive","enrollment":17},{"nctId":"NCT06943482","phase":"PHASE4","title":"Comparing Effectiveness of Steroids and Methotrexate in Treatment of Chronic Inflammatory Breast Disease","status":"NOT_YET_RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2025-07-01","conditions":"Idiopathic Granulomatous Mastitis","enrollment":40},{"nctId":"NCT02766465","phase":"PHASE2","title":"Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2017-03-16","conditions":"Sickle Cell Disease","enrollment":138},{"nctId":"NCT02378298","phase":"PHASE4","title":"Rituximab (RTX) Therapy in Patients With Active TAO","status":"COMPLETED","sponsor":"Göteborg University","startDate":"2011-12","conditions":"Ophthalmopathy, Thyroid-Associated","enrollment":38},{"nctId":"NCT03674424","phase":"PHASE2","title":"Avelumab as Neoadjuvant Therapy in Subjects With Urothelial Muscle Invasive Bladder Cancers (AURA Trial)","status":"COMPLETED","sponsor":"Jules Bordet Institute","startDate":"2018-06-01","conditions":"Non-metastatic Muscle Invasive Bladder Cancer","enrollment":137},{"nctId":"NCT06498089","phase":"PHASE4","title":"A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's Arteritis","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2024-06-28","conditions":"Takayasu Arteritis","enrollment":124},{"nctId":"NCT05102448","phase":"PHASE4","title":"Comparison of Tofacitinib and Methotrexate in Takayasu's Arteritis","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2021-11-01","conditions":"Takayasu Arteritis","enrollment":76},{"nctId":"NCT01393639","phase":"PHASE2","title":"Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-09-27","conditions":"Rheumatoid Arthritis","enrollment":323},{"nctId":"NCT04311567","phase":"PHASE4","title":"Effects of Tofacitinib vs Methotrexate on Rheumatoid Arthritis Interstitial Lung Disease","status":"TERMINATED","sponsor":"Vastra Gotaland Region","startDate":"2020-11-07","conditions":"Rheumatoid Arthritis, Interstitial Lung Disease Due to Systemic Disease (Disorder), RA","enrollment":3},{"nctId":"NCT05623592","phase":"PHASE2","title":"Methotrexate as Remission Maintenance Therapy After Remission-Induction With Tocilizumab and Glucocorticoids in Giant Cell Arteritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Bonn","startDate":"2022-11-23","conditions":"Giant Cell Arteritis","enrollment":52},{"nctId":"NCT03959241","phase":"PHASE3","title":"TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2019-06-25","conditions":"Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplasia","enrollment":431},{"nctId":"NCT01829295","phase":"PHASE3","title":"Methotrexate and Mycophenolate Mofetil for UVEITIS","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2013-08","conditions":"Uveitis","enrollment":216},{"nctId":"NCT00579644","phase":"PHASE3","title":"Treatment of Early RA: Minocycline in Combination With Methotrexate vs Methotrexate Alone","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2001-03-28","conditions":"Rheumatoid Arthritis","enrollment":91},{"nctId":"NCT00003838","phase":"PHASE2","title":"Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1999-04-15","conditions":"Myeloproliferative Disorders, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia","enrollment":202},{"nctId":"NCT01951885","phase":"PHASE3","title":"Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2014-07-07","conditions":"Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":101},{"nctId":"NCT00003910","phase":"PHASE2","title":"Methotrexate With or Without Cyclophosphamide in Treating Patients With Lymphocytic Leukemia","status":"TERMINATED","sponsor":"Eastern Cooperative Oncology Group","startDate":"1999-09-15","conditions":"Leukemia","enrollment":59},{"nctId":"NCT00335140","phase":"PHASE2","title":"Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma","status":"TERMINATED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2007-08-23","conditions":"Lymphoma","enrollment":26},{"nctId":"NCT01572662","phase":"PHASE2","title":"Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-04-11","conditions":"Leukemia, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia","enrollment":201},{"nctId":"NCT00045305","phase":"PHASE2","title":"Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2006-10-24","conditions":"Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms","enrollment":17},{"nctId":"NCT00057954","phase":"PHASE2","title":"Reduced-Intensity Regimen Before Allogeneic Transplant for Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma","status":"TERMINATED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2005-11-09","conditions":"Lymphoma","enrollment":6},{"nctId":"NCT00323960","phase":"PHASE3","title":"Five-year Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis","status":"COMPLETED","sponsor":"Istituto Giannina Gaslini","startDate":"2006-05-31","conditions":"Juvenile Dermatomyositis","enrollment":139},{"nctId":"NCT02345850","phase":"PHASE3","title":"Calcineurin Inhibitor-Free Interventions BMT CTN 1301 for Prevention of Graft-versus-Host Disease (BMT CTN 1301)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2015-08","conditions":"Acute Leukemia, Myelodysplasia","enrollment":346},{"nctId":"NCT04610476","phase":"PHASE3","title":"Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis","status":"UNKNOWN","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2020-10-19","conditions":"Psoriatic Arthritis, Withdrawal, Reduction","enrollment":270},{"nctId":"NCT01491815","phase":"PHASE4","title":"Active Conventional Therapy Compared to Three Different Biologic Treatments in Early Rheumatoid Arthritis With Subsequent Dose Reduction","status":"UNKNOWN","sponsor":"Karolinska Institutet","startDate":"2012-12-14","conditions":"Rheumatoid Arthritis","enrollment":812},{"nctId":"NCT02466581","phase":"PHASE4","title":"Dose Reduction for Early Rheumatoid Arthritis Patients With Low Disease Activity","status":"UNKNOWN","sponsor":"Karolinska Institutet","startDate":"2015-02-03","conditions":"Rheumatoid Arthritis","enrollment":25},{"nctId":"NCT04124861","phase":"NA","title":"Withdraw Drug in Stable IgG4-Related Disease","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2020-06-23","conditions":"Autoimmune Diseases","enrollment":138},{"nctId":"NCT02313870","phase":"PHASE3","title":"Topical Steroids Alone or Associated With Methotrexate in Bullous Pemphigoid","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2008-01-22","conditions":"Bullous Pemphigoid","enrollment":322},{"nctId":"NCT01471444","phase":"PHASE3","title":"Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-11-02","conditions":"Disorder Related to Bone Marrow Transplantation, Leukemia, Transplantation Infection","enrollment":256},{"nctId":"NCT04622956","phase":"PHASE1, PHASE2","title":"GVHD Prophylaxis With Methotrexate in Haploidentical HCT Using Posttransplant Cyclophosphamide","status":"UNKNOWN","sponsor":"University of Sao Paulo General Hospital","startDate":"2020-10-07","conditions":"Graft Vs Host Disease, Hematopoietic Neoplasm","enrollment":47},{"nctId":"NCT00919503","phase":"PHASE2","title":"Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2009-07-31","conditions":"Non-Neoplastic Hematologic and Lymphocytic Disorder","enrollment":98},{"nctId":"NCT04944524","phase":"PHASE4","title":"Comparison of Tofacitinib and Methotrexate in the Maintained Treatment of GPA","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2021-07-01","conditions":"Granulomatosis With Polyangiitis","enrollment":66},{"nctId":"NCT00860574","phase":"PHASE2","title":"Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2009-02","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission","enrollment":96},{"nctId":"NCT02129582","phase":"PHASE1","title":"Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2014-11-05","conditions":"Acute Myeloid Leukemia, Hematologic Malignancies, Acute Lymphocytic Leukemia","enrollment":14},{"nctId":"NCT03692416","phase":"PHASE3","title":"The Effect of Some Drugs Used in Treatment of Vasculitis on the Complement System in Children","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2018-11-11","conditions":"Vasculitis","enrollment":70},{"nctId":"NCT04127721","phase":"PHASE2","title":"Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplantation","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-09-22","conditions":"Allogeneic Stem Cell Transplant Recipient, Hematologic and Lymphocytic Disorder, Hematopoietic and Lymphoid Cell Neoplasm","enrollment":""},{"nctId":"NCT01490723","phase":"PHASE2","title":"Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-01","conditions":"Leukemia, Lymphoma","enrollment":20},{"nctId":"NCT00553202","phase":"PHASE2","title":"Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2008-01","conditions":"Leukemia","enrollment":158},{"nctId":"NCT02000336","phase":"PHASE3","title":"Comparison of the Effectiveness of Two Different Dosages of Cortisone Compared to Placebo in Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Prof. Dr. rer. nat. H.J. Trampisch","startDate":"2014-01","conditions":"Progression of Rheumatoid Arthritis","enrollment":395},{"nctId":"NCT00857389","phase":"PHASE2","title":"Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-03-02","conditions":"Stem Cell Transplantation, Leukemia, Lymphoma","enrollment":60},{"nctId":"NCT01791153","phase":"PHASE3","title":"An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-07-22","conditions":"Giant Cell Arteritis","enrollment":251},{"nctId":"NCT01529827","phase":"PHASE2","title":"Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2012-02-28","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission","enrollment":94},{"nctId":"NCT00382109","phase":"PHASE3","title":"Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2007-03","conditions":"B-cell Childhood Acute Lymphoblastic Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Graft Versus Host Disease","enrollment":146},{"nctId":"NCT02531633","phase":"PHASE3","title":"Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2015-10-16","conditions":"Giant Cell Arteritis","enrollment":161},{"nctId":"NCT01875237","phase":"PHASE1, PHASE2","title":"Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-12-27","conditions":"Leukemia, Myeloma, Myeloproliferative Diseases","enrollment":3},{"nctId":"NCT02042690","phase":"PHASE3","title":"Haplo-identical HSCT Versus Chemotherapy for Adult Acute Lymphoblastic Leukemia Patients","status":"COMPLETED","sponsor":"Peking University","startDate":"2014-07","conditions":"Acute Lymphoblastic Leukemia","enrollment":131},{"nctId":"NCT00520130","phase":"PHASE1, PHASE2","title":"Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-10-30","conditions":"Myelodysplastic Syndrome, Hodgkin's Lymphoma, Non-Hodgkin's Disease","enrollment":92},{"nctId":"NCT02208037","phase":"PHASE2","title":"Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2014-08","conditions":"Acute Leukemia, Chronic Myelogenous Leukemia, Myelodysplasia","enrollment":279},{"nctId":"NCT00426101","phase":"PHASE3","title":"Treatment Protocol for Hemophagocytic Lymphohistiocytosis 2004","status":"COMPLETED","sponsor":"Karolinska University Hospital","startDate":"2004-01","conditions":"Hemophagocytic Lymphohistiocytosis","enrollment":368},{"nctId":"NCT00609739","phase":"PHASE1, PHASE2","title":"Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"1999-06","conditions":"Leukemia","enrollment":1},{"nctId":"NCT01565616","phase":"PHASE2","title":"Bone Marrow Transplantation in Young Adults With Severe Sickle Cell Disease","status":"COMPLETED","sponsor":"Emory University","startDate":"2012-03","conditions":"Sickle Cell Disease","enrollment":22},{"nctId":"NCT00245037","phase":"PHASE1, PHASE2","title":"Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer","status":"COMPLETED","sponsor":"OHSU Knight Cancer Institute","startDate":"2005-06","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":147},{"nctId":"NCT00343785","phase":"PHASE2","title":"Cyclophosphamide and Anti-thymocyte Globulin Followed By Methotrexate and Cyclosporine in Preventing Chronic Graft-Versus-Host Disease in Patients With Severe Aplastic Anemia Undergoing Donor Bone Marrow Transplant","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2006-02","conditions":"Aplastic Anemia","enrollment":21},{"nctId":"NCT00480272","phase":"PHASE4","title":"Prospective Study on Intensive Early Rheumatoid Arthritis Treatment","status":"COMPLETED","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2007-05","conditions":"Rheumatoid Arthritis","enrollment":251},{"nctId":"NCT01661140","phase":"PHASE4","title":"A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Severe Active Rheumatoid Arthritis, Comparing Tapering Versus Maintaining the Methotrexate Dosage","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2012-09","conditions":"Rheumatoid Arthritis","enrollment":427},{"nctId":"NCT02141100","phase":"PHASE1, PHASE2","title":"Study of 6-Thioguanine in Combination With 6-Mercaptopurine During Maintenance Therapy of Childhood Lymphoma","status":"WITHDRAWN","sponsor":"Kjeld Schmiegelow","startDate":"2014-07","conditions":"Non-Hodgkin Lymphoma","enrollment":""},{"nctId":"NCT00028600","phase":"PHASE2","title":"Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2001-11","conditions":"Multiple Myeloma, Plasma Cell Neoplasm","enrollment":60},{"nctId":"NCT00053196","phase":"PHASE2","title":"Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2002-12","conditions":"Leukemia, Lymphoma, Multiple Myeloma","enrollment":82},{"nctId":"NCT02799888","phase":"PHASE2","title":"Maraviroc-Based GVHD Prophylaxis in HLA-Unrelated and HLA-Mismatched Related Transplantation","status":"UNKNOWN","sponsor":"Affiliated Hospital to Academy of Military Medical Sciences","startDate":"2014-04","conditions":"Graft-versus-host Disease, Hematopoietic Stem Cell Transplantation","enrollment":40},{"nctId":"NCT02779114","phase":"PHASE3","title":"RETRO (REduction of Therapy in RA Patients in Ongoing Remission)","status":"UNKNOWN","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2009-01","conditions":"Rheumatoid Arthritis","enrollment":318},{"nctId":"NCT00651040","phase":"PHASE3","title":"Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With PM and DM","status":"COMPLETED","sponsor":"Institute of Rheumatology, Prague","startDate":"2008-05","conditions":"Polymyositis, Dermatomyositis","enrollment":31},{"nctId":"NCT01518153","phase":"PHASE2","title":"Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-02","conditions":"Leukemia, Lymphoma, Myeloma","enrollment":16},{"nctId":"NCT00402558","phase":"PHASE1","title":"Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-05","conditions":"Myelodysplastic Syndrome, Leukemia","enrollment":15},{"nctId":"NCT01488253","phase":"PHASE2","title":"Sirolimus/Tacrolimus Combination After HLA Matched Related Peripheral Blood Stem Cell Transplants","status":"TERMINATED","sponsor":"The Korean Society of Blood and Marrow Transplantation","startDate":"2012-01","conditions":"Acute Leukemia in Remission, Myelodysplastic Syndromes, Leukemia, Myeloid, Chronic-Phase","enrollment":3},{"nctId":"NCT00002665","phase":"PHASE2","title":"SWOG-9400 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Previously Untreated Acute Lymphocytic Leukemia","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"1995-07","conditions":"Leukemia, Neutropenia, Thrombocytopenia","enrollment":50},{"nctId":"NCT00613457","phase":"PHASE3","title":"Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Associazione Italiana Ematologia Oncologia Pediatrica","startDate":"2000-09","conditions":"Leukemia","enrollment":2039},{"nctId":"NCT01059773","phase":"PHASE4","title":"A Safety and Efficacy Study of Ustekinumab in Patients With Plaque Psoriasis Who Have Had an Inadequate Response to Methotrexate","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2009-10","conditions":"Psoriasis","enrollment":490},{"nctId":"NCT00322101","phase":"PHASE3","title":"Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2006-01","conditions":"Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Acute Myeloid Leukemia/Transient Myeloproliferative Disorder, Adult Acute Myeloid Leukemia in Remission","enrollment":25},{"nctId":"NCT00654368","phase":"PHASE4","title":"CAMEO: Canadian Methotrexate and Etanercept Outcome Study","status":"COMPLETED","sponsor":"Amgen","startDate":"2008-06","conditions":"Rheumatoid Arthritis","enrollment":258},{"nctId":"NCT00810199","phase":"PHASE3","title":"A Study of Tocilizumab and Methotrexate Treatment Strategies (Adding Tocilizumab to Methotrexate Versus Switching to Tocilizumab) in Patients With Active Rheumatoid Arthritis With Inadequate Response to Prior Methotrexate Treatment","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-03","conditions":"Rheumatoid Arthritis","enrollment":556},{"nctId":"NCT00720629","phase":"PHASE2","title":"Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation","status":"TERMINATED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2007-12","conditions":"Graft Versus Host Disease","enrollment":8},{"nctId":"NCT01786018","phase":"PHASE2","title":"Thiotepa, Busulfan and Fludarabin for pt With Refractory/Early Relapsed Aggressive B-cell Non Hodgkin Lymphomas","status":"UNKNOWN","sponsor":"Azienda Ospedaliera San Giovanni Battista","startDate":"2013-02","conditions":"B-cell Lymphoma Refractory","enrollment":42},{"nctId":"NCT00918554","phase":"PHASE4","title":"Efficacy Study of Methotrexate to Treat Sarcoid-associated Uveitis","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2009-09","conditions":"Sarcoid-associated Uveitis, Ocular Sarcoidosis, Macular Edema","enrollment":7},{"nctId":"NCT00940524","phase":"PHASE1","title":"Induction Therapy With Cytarabine, High-Dose Mitoxantrone and Dasatinib for Patients With Philadelphia-Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2009-07","conditions":"Leukemia, Acute Lymphoblastic Leukemia","enrollment":7},{"nctId":"NCT01079988","phase":"PHASE4","title":"Study of Therapeutic Options for Subjects Discontinuing Efalizumab and Experiencing Disease Recurrence","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2004-02","conditions":"Psoriasis","enrollment":41},{"nctId":"NCT00002961","phase":"PHASE3","title":"Chemotherapy With or Without Total-Body Irradiation Prior to Bone Marrow Transplantation in Treating Children With Acute Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"Children's Hospital of Philadelphia","startDate":"1995-10","conditions":"Leukemia","enrollment":43},{"nctId":"NCT00858780","phase":"PHASE4","title":"Study Comparing The Effect On Disease Activity When Reducing Or Discontinuing Etanercept In Subjects With RA","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-01","conditions":"Rheumatoid Arthritis","enrollment":91},{"nctId":"NCT00443430","phase":"PHASE4","title":"Trial of Early Aggressive Drug Therapy in Juvenile Idiopathic Arthritis","status":"COMPLETED","sponsor":"Seattle Children's Hospital","startDate":"2007-05","conditions":"Juvenile Chronic Polyarthritis, Juvenile Idiopathic Arthritis, Juvenile Rheumatoid Arthritis","enrollment":85},{"nctId":"NCT01810926","phase":"PHASE2","title":"T&B Depletion Non Malignant","status":"UNKNOWN","sponsor":"Franco Locatelli","startDate":"2011-09","conditions":"Graft Versus Host Disease","enrollment":130},{"nctId":"NCT01177371","phase":"PHASE2","title":"High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"1988-03","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Megakaryoblastic Leukemia (M7)","enrollment":13},{"nctId":"NCT00689845","phase":"NA","title":"Combination Chemotherapy and Rituximab in Treating Patients With Primary Mediastinal Diffuse Large B-Cell Lymphoma","status":"UNKNOWN","sponsor":"University Hospital Southampton NHS Foundation Trust","startDate":"2007-06","conditions":"Lymphoma","enrollment":120},{"nctId":"NCT00554710","phase":"PHASE4","title":"Top Down Versus Step Up Strategies in Crohn's Disease","status":"COMPLETED","sponsor":"Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW","startDate":"2001-05","conditions":"Crohn's Disease","enrollment":129}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":16,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Methotrexate (tapering dose)","genericName":"Methotrexate (tapering dose)","companyName":"Hoffmann-La Roche","companyId":"roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Methotrexate inhibits dihydrofolate reductase, blocking folate metabolism and reducing DNA synthesis and cell proliferation. Used for Acute lymphoblastic leukemia (ALL), Osteosarcoma, Breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}